In-licensing novel candidates for sight-threatening diseases 469 7th Avenue Suite 221 New York, NY 10018 Phone: (212) 359-9491 E-Mail: contact@imagenbiotech.com Contact: Matthew Feinsod, MD Industry S
Spurred by the commercial success of Lucentis, start-ups developing new therapeutics for AMD tap into a growing understanding of the pathogenesis of the disease. It has been three years since Roche
Taking a vascular view of eye disease 2300 McDermott Road Suite 200-147 Plano, TX 75025 Phone: (214) 577-5999 Web Site: www.macuclear.com Contact : Philip G. Ralston, Jr., President & CEO Industry Se
Pursuing new targets for treating blinding eye diseases 21720 23rd Drive SE Suite 120 Bothell, WA 98021 Phone: (425) 527-3260 Web Site: www.acucela.com Contact: Ryo Kubota, MD, PhD, President & CEO In